These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 23676092)
1. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma. El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092 [No Abstract] [Full Text] [Related]
2. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma. Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361 [TBL] [Abstract][Full Text] [Related]
3. [Squamous cell carcinoma in a patient receiving sorafenib]. Adnot-Desanlis L; Bernard P; Reguiaï Z Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823 [TBL] [Abstract][Full Text] [Related]
4. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084 [No Abstract] [Full Text] [Related]
5. Case of sorafenib-induced thyroid storm. Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115 [No Abstract] [Full Text] [Related]
6. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206 [TBL] [Abstract][Full Text] [Related]
8. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report]. Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860 [TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404 [TBL] [Abstract][Full Text] [Related]
10. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. Kashima T; Ohno Y; Tachibana M Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573 [No Abstract] [Full Text] [Related]
11. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)]. Rexer H; Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992 [No Abstract] [Full Text] [Related]
17. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320 [TBL] [Abstract][Full Text] [Related]
18. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma. Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578 [TBL] [Abstract][Full Text] [Related]
19. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma. Sil A; Das NK Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183 [TBL] [Abstract][Full Text] [Related]
20. [Side effects of sorafenib and countermeasures]. Nakayama M; Arai Y; Nishimura K Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]